证券代码：002173 证券简称：创新医疗 公告编号：2023-026 创新医疗管理股份有限公司 参与方式一：在微信小程序中搜索"创新医疗投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"创新医疗投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：董事长陈海军先生，总裁代行财务总监马建 建先生，独立董事余景选先生，董事会秘书郭立丹女士。（如有特殊情况，参与 1 / 2 人员会有调整） 关于召开 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 创新医疗管理股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 5 月 19 日（星期五）15:00 至 17:00 在"创新医疗投资者关系"小程序举行 2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥204,206,456.23, representing a 19.22% increase compared to ¥171,290,921.92 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥2,159,886.00, an improvement of 84.83% from a loss of ¥14,238,149.54 in the previous year[5] - The net cash flow from operating activities was ¥12,372,882.62, a significant increase of 117.01% compared to a negative cash flow of ¥72,743,214.00 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 204,206,456.23, an increase of 19.2% compared to CNY 171,290,921.92 in Q1 2022[16] - Net loss for Q1 2023 was CNY 2,096,068.75, a significant improvement from a net loss of CNY 14,211,186.74 in Q1 2022[16] - Cash inflow from operating activities was CNY 222,244,830.87, compared to CNY 133,976,301.93 in the previous year, marking a growth of 66.3%[18] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.0048, an improvement from CNY -0.0320 in Q1 2022[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,327,789,036.86, a slight decrease of 0.51% from ¥2,339,662,759.53 at the end of the previous year[5] - Total liabilities decreased to CNY 424,636,503.68 from CNY 434,414,157.60 year-over-year, a reduction of 2%[16] - Total equity attributable to shareholders of the parent company was CNY 1,902,153,166.88, slightly down from CNY 1,904,313,052.88[16] - The company reported a total of ¥1,556,083,863.78 in non-current assets, down from ¥1,568,014,889.21[14] Cash Flow - The company's cash and cash equivalents at the end of the period amount to ¥642,346,295.33, down from ¥658,484,959.64 at the beginning of the year[14] - The net cash flow from operating activities for Q1 2023 was $12,372,882.62, a significant improvement compared to a net outflow of $72,743,214.00 in Q1 2022[19] - Total cash outflow from operating activities amounted to $209,871,948.25, slightly up from $206,719,515.93 in the previous year[19] - The net cash flow from investing activities was -$22,266,188.74, worsening from -$9,829,759.24 in Q1 2022[19] - Cash and cash equivalents at the end of Q1 2023 stood at $642,379,270.35, compared to $132,404,379.55 at the end of Q1 2022[19] - The company reported a total cash outflow from financing activities of $6,065,486.72, an improvement from $10,733,492.80 in the same quarter last year[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 32,942[10] - The largest shareholder, Chen Xiaying, holds 17.13% of shares, totaling 77,616,997 shares, with 3,700,000 shares pledged[10] - The top ten shareholders include several investment funds, indicating a diverse ownership structure[11] - The company has a total of 77,616,997 unrestricted shares held by its largest shareholder, Chen Xiaying[11] Operational Insights - Accounts receivable increased by 33.28% to ¥68,720,668.89, primarily due to increased revenue from subsidiary hospitals[7] - Prepayments surged by 488,134.75% to ¥29,294,085.13, mainly due to a policy adjustment that led to a prepayment of ¥29.25 million from medical insurance[7] - Sales expenses rose by 38.61% to ¥3,075,618.11, attributed to increased marketing efforts in health check services by a subsidiary[7] - The company reported a significant increase in operating income, with cash received from sales and services rising by 65.98% to ¥215,860,854.82[8] - The company received government subsidies amounting to ¥270,623.70 during the reporting period[6] Future Outlook - The company plans to continue expanding its market presence and enhancing its service offerings in the healthcare sector[5] - The company continues to explore market expansion opportunities and new product development strategies to enhance future growth prospects[16] - The company has not received the performance compensation of 4,485,506 shares from Kanghan Investment as of now, which adds uncertainty to future financials[12] - The company is actively taking legal measures to recover the performance compensation owed[12] Miscellaneous - The first quarter report was not audited, which may affect the reliability of the financial data presented[20] - Research and development expenses were not explicitly reported, indicating a potential area for future focus and investment[16]

创新医疗管理股份有限公司2022年年度报告全文 创新医疗管理股份有限公司 2022 年年度报告 ...

证券代码：002173 证券简称：千足珍珠 千足珍珠集团股份有限公司投资者关系活动记录表 编号：2015-02 | --- | --- | --- | |------------------------------------|------------------------------|----------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 | 现场投资者接待日活动 | | 参与单位名称及人员姓名 | | 北京立名投资管理有限公司赵悦，浙商证券研究所程艳华、曹 | | | | 梦悦、刘楠，深圳睿泉毅信投资管理有限公司吴雅春，上海通 | | | | 金投资有限公司陈坤，民生证券毕海委，中信建投证券陈萌， | | | | 中海基金管理有限公司焉娇、郑辰，鹏华基金金笑非，东海证 ...

证券代码：002173 证券简称：千足珍珠 千足珍珠集团股份有限公司投资者关系活动记录表 编号：2015-01 | --- | --- | --- | |------------------------------------------------------|------------------------------|----------------------------------------------------------------------------------| | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 | 现场投资者接待日活动 | | 参与单位名称及人员姓名 | 无 | | | 时间 | 2015 年 5 月 18 日 | 上午 9 点 30 分至 11 点 30 分 | | 地点 | 公司五楼会议室 | | | 上市公司接待人员姓名 | | 董事长兼总裁陈海军、董秘兼副总裁马三光、财务总监洪全付、 ...

Group 1: Company Overview - The company operates in two main sectors: pearl processing and sales, and medical services [3] - The pearl industry faces significant challenges due to complex international and domestic environments, with a notable decline in pearl production and prices remaining low despite reduced supply [3] Group 2: Financial Performance - In the first half of 2016, the company reported revenue of 36.8964 million yuan, a decrease of 51.79% compared to the same period last year [3] - The net profit for the same period was -27.8095 million yuan, down 64.44% year-on-year [3] Group 3: Hospital Integration and Performance - The company has acquired three hospitals and is focused on integrating them, with the goal of building a distinctive and innovative healthcare industry cluster [4] - As of June 30, 2016, two of the hospitals have met half of their promised performance for the year, while one hospital is underperforming due to seasonal patient discharge issues [4] Group 4: Future Strategies - The company plans to unify management across the three hospitals and establish effective management processes [6] - Future acquisitions will focus on profitable hospitals, and the company does not plan to build new hospitals or partner with non-profit public hospitals due to high risks and costs [5]

证券代码：002173 证券简称：*ST 创疗 创新医疗管理股份有限公司投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |--------------------------------------|----------------------------------|----------------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | 每日经济新闻 | 记者 沈溦 | | 时间 | 2016 年 9 月 28 日上午 | 10 点 ~11 点 | | 地点 | 浙江省杭州市求是路 | 8 号公元大厦北楼 303A 室 | | 上市公司接待人员姓名 | 董事会秘书兼副总裁傅震刚 | | | 现场采访活动主 ...

编号：2016-03 √特定对象调研 □分析师会议 投资者关系 √媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名 国投瑞银张佳荣、浦银安盛刘诗瑶、上投摩根方珏涵、交银施罗德楼慧源、富国 称及人员姓 基金姜恩铸、鹏华基金金笑非、陈璇淼、中邮基金容杰、泰信基金徐慕浩、中海 名 基金郑辰、民生通惠罗丹、中原证券张洋、太平洋证券耿广棋、程艳华、西部证 券王宗凯、趋时资产罗会礼、长安信托杨小馨、证券时报吕婧、李小平、滚石投 资王广军、王超、上海昶享资产徐幸福、东方创新毕海委、立名投资柯良友、致 君资产李涛、同犇投资周雅洁、涌悦资产成胜、彤源投资庄琰、源实资产江琦、 浙商证券杨云、曹梦悦、刘楠、中信证券曹阳、九富投资王新华、范瑞、中欧基金 姜祎、李欣 证券代码：002173 证券简称：*ST 创疗 创新医疗管理股份有限公司投资者关系活动记录表 | --- | --- | |------------|----------------------------------------------------------------------| | 时间 | 2016 年 10 月 ...